A) % proliferated CD19+ B cells

- without milatuzumab
- with IVIG
- with milatuzumab

B) MIF concentration

- without milatuzumab
- with IVIG
- with milatuzumab

C) % DAPI high positive cells

- without milatuzumab
- with IVIG
- with milatuzumab

number of cells vs. CFSE fluorescence intensity

97.5%, 96%, 92%